AGTR1 and hydrops fetalis: These results, investigated in the context of the ELITE II trial, strengthen the conclusion that captopril treatment should remain the preferred treatment over AT1 receptor antagonists due to the overall results favoring captopril for patients with HF in the absence of adverse events [239,240].